Latest News

March 23, 2023
March 23, 2023
Categories

The Spring 2023 advocacy blog Considering Clinical Trials is now available

Do you like it?
Read more
March 21, 2023
March 21, 2023
Categories

In this video interview, Dr. Neha Vapiwala discusses the INDICATE (EA8191) trial and changing the trajectory of prostate cancer through radiation and imaging techniques

Do you like it?
Read more
March 8, 2023
March 8, 2023
Categories

The ComboMATCH patient registration trial and three treatment trials are now open

Do you like it?
Read more
February 27, 2023
February 27, 2023
Categories

The TAILORx trial continues to provide reassurance that many women with early breast cancer can safely forego chemotherapy

Do you like it?
Read more
February 23, 2023
February 23, 2023
Categories

A focus on the DREAMseq trial reveals data-driven clinical insights into the selection of first-line treatment options for patients with BRAF-mutated metastatic melanoma

Do you like it?
Read more
Load more

Tweets

ECOG-ACRIN Cancer Research Group Follow

Biomarker-driven medical research involving adults who have or are at risk of developing cancer

eaonc
eaonc ECOG-ACRIN Cancer Research Group @eaonc ·
21h

You may be eligible to participate in a #rectalcancer study (MSI-H or dMMR) that could discover if treatment w/ #immunotherapy + radiation prior to surgery is better than the usual approach of radiation, surgery, and chemotherapy. More: https://bit.ly/ea2201trial #colorectalcancer

Reply on Twitter 1639266450086023172 Retweet on Twitter 1639266450086023172 2 Like on Twitter 1639266450086023172 2 Twitter 1639266450086023172
eaonc ECOG-ACRIN Cancer Research Group @eaonc ·
23 Mar

You may be eligible to participate in a #BladderCancer study that could help find out which treatment approach – chemo & radiation versus chemo & radiation & durvalumab #immunotherapy – is better. Learn more: https://bit.ly/ea8185inspire

Reply on Twitter 1638979421418983424 Retweet on Twitter 1638979421418983424 1 Like on Twitter 1638979421418983424 3 Twitter 1638979421418983424
eaonc ECOG-ACRIN Cancer Research Group @eaonc ·
23 Mar

#Clinicaltrial EA6194 is using a neoadjuvant approach for patients with operable #melanoma. The study will determine both the effect of adding neoadjuvant immunotherapy alone, as well as the effect of adding neoadjuvant immunotherapy plus CMP-001. More: https://bit.ly/EA6194

Reply on Twitter 1638934192347299840 Retweet on Twitter 1638934192347299840 Like on Twitter 1638934192347299840 Twitter 1638934192347299840
Load More

About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More

Home

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More

ECOG-ACRIN by the Numbers

Home
53

Active Clinical Trials

Home
1300

Participating Institutions

Home
67

International Sites

Home
15000

Individual Members

Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).

ECOG-ACRIN Cancer Research Group